140 related articles for article (PubMed ID: 9881484)
1. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment.
Dufour JF; DeLellis R; Kaplan MM
Dig Dis Sci; 1998 Dec; 43(12):2573-6. PubMed ID: 9881484
[TBL] [Abstract][Full Text] [Related]
2. Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years.
Guerret S; Desmoulière A; Chossegros P; Costa AM; Badid C; Trépo C; Grimaud JA; Chevallier M
J Viral Hepat; 1999 Mar; 6(2):125-33. PubMed ID: 10607223
[TBL] [Abstract][Full Text] [Related]
3. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon.
Toccaceli F; Laghi V; Capurso L; Koch M; Sereno S; Scuderi M;
J Viral Hepat; 2003 Mar; 10(2):126-33. PubMed ID: 12614469
[TBL] [Abstract][Full Text] [Related]
4. Reversibility of cirrhosis in chronic hepatitis B.
Malekzadeh R; Mohamadnejad M; Rakhshani N; Nasseri-Moghaddam S; Merat S; Tavangar SM; Sohrabpour AA
Clin Gastroenterol Hepatol; 2004 Apr; 2(4):344-7. PubMed ID: 15067631
[TBL] [Abstract][Full Text] [Related]
5. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
6. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
7. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
[TBL] [Abstract][Full Text] [Related]
8. [Computerized histological analysis in chronic viral hepatitis].
Hassan C; Tavani PD; Serafini B
Pathologica; 1999 Jun; 91(3):173-8. PubMed ID: 10536462
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
[TBL] [Abstract][Full Text] [Related]
10. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders.
Nelson DR; Lauwers GY; Lau JY; Davis GL
Gastroenterology; 2000 Apr; 118(4):655-60. PubMed ID: 10734016
[TBL] [Abstract][Full Text] [Related]
12. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
[TBL] [Abstract][Full Text] [Related]
13. Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.
Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():327-34. PubMed ID: 27051280
[TBL] [Abstract][Full Text] [Related]
14. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.
Lau DT; Kleiner DE; Ghany MG; Park Y; Schmid P; Hoofnagle JH
Hepatology; 1998 Oct; 28(4):1121-7. PubMed ID: 9755252
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C.
McHutchison JG; Patel K; Schiff ER; Gitlin N; Mur RE; Everson GT; Carithers RL; Davis GL; Marcellin P; Shiffman ML; Harvey J; Albrecht JK;
Aliment Pharmacol Ther; 2008 Mar; 27(5):422-32. PubMed ID: 18081733
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of interferon-treated chronic hepatitis C and serum hepatic fibrosis markers.
Ueno T; Ide T; Hashimoto O; Uchimura Y; Torimura T; Kumashiro R; Inuzuka S; Sata M
Hepatogastroenterology; 2001; 48(40):1124-8. PubMed ID: 11490815
[TBL] [Abstract][Full Text] [Related]
17. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
18. Reversibility of hepatic fibrosis in autoimmune hepatitis.
Dufour JF; DeLellis R; Kaplan MM
Ann Intern Med; 1997 Dec; 127(11):981-5. PubMed ID: 9412303
[TBL] [Abstract][Full Text] [Related]
19. Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients.
Nirei K; Matsumura H; Kumakawa M; Matsumoto N; Nakamura H; Yamagami H; Matsuoka S; Moriyama M
Int J Med Sci; 2017; 14(1):45-52. PubMed ID: 28138308
[No Abstract] [Full Text] [Related]
20. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
